<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002692</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064434</org_study_id>
    <secondary_id>MRC-CR05</secondary_id>
    <secondary_id>EU-95032</secondary_id>
    <nct_id>NCT00002692</nct_id>
  </id_info>
  <brief_title>Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver</brief_title>
  <official_title>A RANDOMISED TRIAL OF INTRAVENOUS VERSUS INTRAHEPATIC ARTERIAL 5-FU AND LEUCOVORIN FOR COLORECTAL LIVER METASTASES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Randomized phase III trial to compare the effectiveness of intravenous infusion or
      intrahepatic infusion of fluorouracil and leucovorin in treating patients with colorectal
      cancer metastatic to the liver.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the survival and response rates of patients with colorectal liver
      metastases treated with intravenous vs. intrahepatic arterial infusion of
      fluorouracil/leucovorin. II. Assess the effect of these 2 treatments on symptoms and quality
      of life of these patients.

      OUTLINE: Randomized study. Patients randomized to Arm II should have a preoperative hepatic
      angiography; at laparotomy, an intrahepatic arterial catheter is fused into the
      gastroduodenal artery to establish an infusion of both lobes of the liver. Arm I:
      Single-Agent Chemotherapy with Drug Modulation. Fluorouracil, 5-FU, NSC-19893; with
      Leucovorin calcium, CF, NSC-3590. Intravenous infusion. Arm II: Single-Agent Chemotherapy
      with Drug Modulation. 5-FU; with CF. Intrahepatic arterial infusion.

      PROJECTED ACCRUAL: 312 patients are expected to be randomized within 3-4 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 1994</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">312</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isolated perfusion</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the colon or rectum
        with metastases confined to the liver and not amenable to surgery

        PATIENT CHARACTERISTICS: Age: Any age Performance status: WHO 0-2 Life expectancy: More
        than 3 months Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at least
        1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 3.5 mg/dL (50
        micromoles/liter) Renal: Not specified Cardiovascular: No uncontrolled heart disease (e.g.,
        congestive heart failure, angina) Other: No uncontrolled infection No other uncontrolled
        medical illness

        PRIOR CONCURRENT THERAPY: No prior fluorouracil (5-FU) for advanced disease More than 6
        months since adjuvant 5-FU (e.g., in AXIS or QUASAR studies)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J. Kerr, MD, FRCP, DSc</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>McArdle C: IV versus IHA 5FU/leucovorin for colorectal liver metastases: preliminary results of the MRC CR05 EORTC 40972 randomised trial. [Abstract] Br J Cancer 85 (suppl 1): A-CT2. 1, 2001.</citation>
  </results_reference>
  <results_reference>
    <citation>McArdle C, Kerr DJ, Ledermann J, et al.: Intravenous (IV) vs intrahepatic (IHA) 5FU/leucovorin for colorectal (CRC) liver metastases: preliminary results of the MRC CR05/EORTC 40972 randomised trial. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-499, 2001.</citation>
  </results_reference>
  <results_reference>
    <citation>McArdle C, Kerr DJ, Ledermann J, et al.: Intravenous (IV) vs intrahepatic arterial (IHA) 5-FU/leucovorin for colorectal (CRC) liver metastasis: preliminary results of the MRC CRO5/EORTC 40972 randomised trial. [Abstract] Eur J Cancer 37 (suppl 6): A-955, s257, 2001.</citation>
  </results_reference>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 20, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2004</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>liver metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

